Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C J Logothetis

Showing results (61-70 of 150) with videos related to

Pageof 15
Sort By:
British Journal of Urology|April 1, 1993
Collecting duct carcinoma of the kidneyM A Dimopoulos, C J Logothetis, A Markowitz, et al.
Cancer|September 15, 1987
Sarcomatoid renal cell carcinoma. A treatable entityA Sella, C J Logothetis, J Y Ro, et al.
Cancer|January 1, 1984
The prognostic significance of endodermal sinus tumor histology among patients treated for stage III nonseminomatous germ cell tumors of the testesC J Logothetis, M L Samuels, A Trindade, et al.
Urology|February 1, 1991
Association of germ cell tumors and Hodgkin's diseaseF H Dexeus, R Kilbourn, C Chong, et al.
Cancer Treatment Reports|January 1, 1985
Combined intravenous and intra-arterial cyclophosphamide, doxorubicin, and cisplatin (CISCA) in the management of select patients with invasive urothelial tumorsC J Logothetis, M L Samuels, D E Selig, et al.
Urologic Oncology|January 13, 2011
Paclitaxel in extensively pretreated nonseminomatous germ cell tumorsA Nazario, R J Amato, L Hutchinson, et al.
British Journal of Urology|June 1, 1991
Cisplatin combination chemotherapy for elderly patients with urothelial tumoursA Sella, C J Logothetis, F H Dexeus, et al.
The Journal of Urology|January 1, 1987
Complete responses in metastatic transitional cell carcinoma of the prostate with cisplatin regimensF H Dexeus, C J Logothetis, M L Samuels, et al.
Cancer Treatment Reports|July 1, 1985
Continuous infusion of vinblastine for advanced hormone-refractory prostate cancerF Dexeus, C J Logothetis, M L Samuels, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 28, 2002
A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III randomized trialK Fizazi, K A Do, X Wang, et al.
Pageof 15

Showing results (61-70 of 150) with videos related to

Sort By:
Pageof 15
British Journal of Urology|April 1, 1993
Collecting duct carcinoma of the kidneyM A Dimopoulos, C J Logothetis, A Markowitz, et al.
Cancer|September 15, 1987
Sarcomatoid renal cell carcinoma. A treatable entityA Sella, C J Logothetis, J Y Ro, et al.
Cancer|January 1, 1984
The prognostic significance of endodermal sinus tumor histology among patients treated for stage III nonseminomatous germ cell tumors of the testesC J Logothetis, M L Samuels, A Trindade, et al.
Urology|February 1, 1991
Association of germ cell tumors and Hodgkin's diseaseF H Dexeus, R Kilbourn, C Chong, et al.
Cancer Treatment Reports|January 1, 1985
Combined intravenous and intra-arterial cyclophosphamide, doxorubicin, and cisplatin (CISCA) in the management of select patients with invasive urothelial tumorsC J Logothetis, M L Samuels, D E Selig, et al.
Urologic Oncology|January 13, 2011
Paclitaxel in extensively pretreated nonseminomatous germ cell tumorsA Nazario, R J Amato, L Hutchinson, et al.
British Journal of Urology|June 1, 1991
Cisplatin combination chemotherapy for elderly patients with urothelial tumoursA Sella, C J Logothetis, F H Dexeus, et al.
The Journal of Urology|January 1, 1987
Complete responses in metastatic transitional cell carcinoma of the prostate with cisplatin regimensF H Dexeus, C J Logothetis, M L Samuels, et al.
Cancer Treatment Reports|July 1, 1985
Continuous infusion of vinblastine for advanced hormone-refractory prostate cancerF Dexeus, C J Logothetis, M L Samuels, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 28, 2002
A 20% dose reduction of the original CISCA/VB regimen allows better tolerance and similar survival rate in disseminated testicular non-seminomatous germ-cell tumors: final results of a phase III randomized trialK Fizazi, K A Do, X Wang, et al.
Pageof 15